MARKET

PFE

PFE

Pfizer
NYSE
26.89
-0.29
-1.07%
After Hours: 26.93 +0.04 +0.15% 19:59 02/27 EST
OPEN
27.12
PREV CLOSE
27.18
HIGH
27.20
LOW
26.81
VOLUME
38.60M
TURNOVER
0
52 WEEK HIGH
42.22
52 WEEK LOW
25.38
MARKET CAP
151.84B
P/E (TTM)
72.44
1D
5D
1M
3M
1Y
5Y
Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
NASDAQ · 3h ago
Should You Pick Johnson & Johnson Stock At $160?
NASDAQ · 3h ago
Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Seeking Alpha · 10h ago
3 Overextended Stocks That Need to Slash Their Dividends ASAP
Investorplace · 12h ago
‘Tripledemic’ burden lower this winter despite COVID impact: Airfinity
Seeking Alpha · 13h ago
Beam stock jumps as Eli Lilly deal drives Q4 beat
Beam Therapeutics reported profits in Q4, exceeding Wall Street projections. The gene-editing company's revenue jumped thanks to a collaboration agreement with Eli Lilly (LLY) The company's stock reached a 52-week high on Tuesday. BEAM signed a deal with Lilly in October.
Seeking Alpha · 14h ago
Eli Lilly talks with Viking Therapeutics may have stalled - report
Eli Lilly's potential pursuit of rival obesity drugmaker Viking Therapeutics may have stalled - report. Viking's shares are now up 94% after the drugmaker released strong phase 2 results for a new drug on Tuesday. The drugmaker was expected to announce a deal with Eli Lilly for $40 to $50 a share.
Seeking Alpha · 15h ago
4 Fortune 500 Industry Leaders For February Dividends
Fortune magazine's 2023 list of 500 biggest U.S. Companies by revenue includes 68 industry leaders. Four of the top ten F500-IL dividend-yielding stocks for February 2024 show positive returns. Energy Transfer LP (ET), Verizon Communications, Pfizer, and Ford Motor are four of the best to buy. Top ten Fortune 500 companies by net gains are projected to be 15.93% to 37.64% for February 2025.
Seeking Alpha · 15h ago
More
About PFE
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Webull offers Pfizer Inc stock information, including NYSE: PFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PFE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PFE stock methods without spending real money on the virtual paper trading platform.